Lantheus Holdings, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Lantheus Holdings, Inc. (LNTH) reported Cash and Cash Equivalents, Period Increase (Decrease) of $37.11 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-20.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-02-20
- Lantheus Holdings, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was $8.82M, a 7.35% increase year-over-year.
- Lantheus Holdings, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was $18.12M, a 65.89% increase year-over-year.
- Lantheus Holdings, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was $12.72M, a 21.80% decline year-over-year.
- Lantheus Holdings, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was -$2.55M.
- Lantheus Holdings, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2018 was $37.11M, a 47.78% increase from fiscal 2017.
- Lantheus Holdings, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $25.11M, a 11.20% increase from fiscal 2016.
- Lantheus Holdings, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $22.58M, a 154.96% increase from fiscal 2015.
- Lantheus Holdings, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $8.86M, a 662.88% increase from fiscal 2014.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2018-12-31 | $8.82M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-20 | $26.94M derived: sum of 2 quarters · filed 2019-02-20 | $39.66M derived: sum of 3 quarters · filed 2019-02-20 | $37.11M 10-K · filed 2019-02-20 |
| 2018-09-30 | $18.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-30 | $30.84M derived: sum of 2 quarters · filed 2018-10-30 | $28.29M 10-Q · filed 2018-10-30 | $36.51M derived: sum of 4 quarters · filed 2019-02-20 |
| 2018-06-30 | $12.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $10.17M 10-Q · filed 2018-08-01 | $18.39M derived: sum of 3 quarters · filed 2019-02-20 | $29.31M derived: sum of 4 quarters · filed 2019-02-20 |
| 2018-03-31 | -$2.55M 10-Q · filed 2018-05-02 | $5.66M derived: sum of 2 quarters · filed 2019-02-20 | $16.59M derived: sum of 3 quarters · filed 2019-02-20 | $32.86M derived: sum of 4 quarters · filed 2019-02-20 |
| 2017-12-31 | $8.21M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-20 | $19.14M derived: sum of 2 quarters · filed 2019-02-20 | $35.41M derived: sum of 3 quarters · filed 2019-02-20 | $25.11M 10-K · filed 2019-02-20 |
| 2017-09-30 | $10.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-30 | $27.20M derived: sum of 2 quarters · filed 2018-10-30 | $16.90M 10-Q · filed 2018-10-30 | $14.88M derived: sum of 4 quarters · filed 2019-02-20 |
| 2017-06-30 | $16.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $5.98M 10-Q · filed 2018-08-01 | $3.96M derived: sum of 3 quarters · filed 2019-02-20 | $2.30M derived: sum of 4 quarters · filed 2019-02-20 |
| 2017-03-31 | -$10.30M 10-Q · filed 2018-05-02 | -$12.31M derived: sum of 2 quarters · filed 2019-02-20 | -$13.97M derived: sum of 3 quarters · filed 2019-02-20 | $2.00M derived: sum of 4 quarters · filed 2019-02-20 |
| 2016-12-31 | -$2.02M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-20 | -$3.67M derived: sum of 2 quarters · filed 2019-02-20 | $12.30M derived: sum of 3 quarters · filed 2019-02-20 | $22.58M 10-K · filed 2019-02-20 |
| 2016-09-30 | -$1.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $14.31M derived: sum of 2 quarters · filed 2017-11-02 | $24.60M 10-Q · filed 2017-11-02 | $31.27M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-06-30 | $15.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-01 | $26.25M 10-Q · filed 2017-08-01 | $32.93M derived: sum of 3 quarters · filed 2018-02-26 | $32.65M derived: sum of 4 quarters · filed 2018-02-26 |
| 2016-03-31 | $10.28M 10-Q · filed 2017-05-02 | $16.96M derived: sum of 2 quarters · filed 2018-02-26 | $16.68M derived: sum of 3 quarters · filed 2018-02-26 | $8.14M derived: sum of 4 quarters · filed 2018-02-26 |
| 2015-12-31 | $6.67M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $6.40M derived: sum of 2 quarters · filed 2018-02-26 | -$2.15M derived: sum of 3 quarters · filed 2018-02-26 | $8.86M 10-K · filed 2018-02-26 |
| 2015-09-30 | -$278.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01 | -$8.82M derived: sum of 2 quarters · filed 2016-11-01 | $2.18M 10-Q · filed 2016-11-01 | -$5.21M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-06-30 | -$8.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $2.46M 10-Q · filed 2016-08-04 | -$4.93M derived: sum of 3 quarters · filed 2017-02-23 | $6.18M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-03-31 | $11.00M 10-Q · filed 2016-05-03 | $3.62M derived: sum of 2 quarters · filed 2017-02-23 | $14.72M derived: sum of 3 quarters · filed 2017-02-23 | |
| 2014-12-31 | -$7.39M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $3.72M derived: sum of 2 quarters · filed 2017-02-23 | $1.16M 10-K · filed 2017-02-23 | |
| 2014-09-30 | $11.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $8.55M 10-Q · filed 2015-11-04 | ||
| 2014-06-30 | -$2.56M 10-Q · filed 2015-08-05 | |||
| 2013-12-31 | -$14.74M 10-K · filed 2016-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |